The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML

About 25% of patients with acute myeloid leukemia (AML) harbor FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations and their prognosis remains poor. Gilteritinib is a FLT3 inhibitor approved by the US FDA for use in adult FLT3-mutated relapsed or refractory AML patients. Mo...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood Cancer J
Auteurs principaux: Qiao, Xinan, Ma, Jun, Knight, Tristan, Su, Yongwei, Edwards, Holly, Polin, Lisa, Li, Jing, Kushner, Juiwanna, Dzinic, Sijana H., White, Kathryn, Wang, Jian, Lin, Hai, Wang, Yue, Wang, Liping, Wang, Guan, Taub, Jeffrey W., Ge, Yubin
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group UK 2021
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8184771/
https://ncbi.nlm.nih.gov/pubmed/34099621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-021-00502-7
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires